Hester buys technology from ICAR - NIHSAD to develop H9N2 vaccine for poultry
This indigenously developed inactivated H9N2 vaccine for poultry is developed using a local isolate, thereby ensuring that the vaccine is made from the local strain and not by importing any exotic strain.
Ahmedabad: Hester has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research - National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry.The agreement was signed on 27 December 2022 at the office...
Login or Register to read the full article
Ahmedabad: Hester has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research - National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry.
The agreement was signed on 27 December 2022 at the office of Agrinnovate India, New Delhi. Agrinnovate is a government entity that acts as an interface between ICAR and the stakeholders in the agriculture sector, which includes technology transfers for vaccine manufacturing in the veterinary sector.
The meeting was attended by Dr. Himanshu Pathak, Director General (DG), ICAR, Dr. B N Tripathi, Deputy DG, ICAR, Dr. Ashok Kumar, Assistant DG, ICAR, Dr. Praveen Malik, CEO, Agrinnovate India, Dr. Aniket Sanyal, Director, NIHSAD, Rajiv Gandhi, CEO & MD, Hester, Dr. Manoj Kumar, CSO, Hester.
Low Pathogenic Avian Influenza H9N2 Strain causes comorbidity in poultry flocks throughout the year, leading to huge economic losses to the poultry farmers. The disease generally has low mortality rate up to 6% but can increase significantly in the presence of other infections. It could also lead to an irreversible egg production drop (up to 50%) in layer birds and a performance loss in broilers.
This indigenously developed inactivated H9N2 vaccine for poultry is developed using a local isolate, thereby ensuring that the vaccine is made from the local strain and not by importing any exotic strain.
As per Agrinovate, the vaccine has passed the sterility, safety, and efficacy testing in experimental trials under laboratory conditions. The vaccine provides protective immunity in chickens for approximately 6 months.
"Hester has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals. Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through Hester's own distribution network, where the demand for this vaccine has already been established," the company stated in a release.
The huge poultry population in India is a key source of livelihood for rural India. Until date, India had no vaccine available for Avian Influenza despite of periodic outbreaks across the country.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd